Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Sponsor:

Mayo Clinic

Code:

NCT06151730

Conditions

Chronic Lymphocytic Leukemia

Hematopoietic and Lymphoid System Neoplasm

Mantle Cell Lymphoma

Marginal Zone Lymphoma

Waldenstrom Macroglobulinemia

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Non-Interventional Study

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information